Loading clinical trials...

Families With Substance Use and Psychosis: A Pilot Study | Clinical Trials | Clareo Health

COMPLETEDNA

Families With Substance Use and Psychosis: A Pilot Study

Treatment Engagement in Families With Substance Use and Psychosis: A Pilot Study

NCT04284813•Mclean Hospital

Summary

The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine (video conferencing). The intervention aims to improve treatment engagement and reduce distress, and it will be delivered via telemedicine (CRAFT-FT). To assess feasibility of the intervention, family members will complete the sessions and provide feedback to refine the treatment manual. Data on client relatives with psychosis will be collected for preliminary assessment purposes. Client relatives will not complete the research study intervention.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ages 18-70.
•Having a relative who:
•1. Is a patient with early course psychosis (DSM-5 schizophrenia, schizoaffective disorder, schizophreniform, psychosis not otherwise specified (NOS), delusional disorder, brief psychotic disorder, major depression with psychosis, and bipolar disorder with psychosis) with first onset in the past 6 years, and
•2. Uses tobacco, alcohol, or cannabis in the past 90 days and/or has no apparent immediate interest in abstinence.
•The person(s) who can best describe the client with psychosis.
•At least 4 days per month contact with the client.
•Access to a computer with internet or mobile phone with video conferencing capabilities.
•Ability to provide written informed consent.
•Speak and read English.
•Ages 18-35.
+4 more criteria

Exclusion Criteria

•DSM-5 moderate or severe substance use disorder in the past year.
•Lifetime psychotic disorder.
•History of domestic violence with the identified patient (IP).
•Psychiatric, cognitive, or medical impairments that would interfere with the ability to follow through with the treatment plan.
•N/A

Locations (1)

McLean Hospital

Belmont, Massachusetts, United States

Key Dates

Start Date

September 24, 2020

Primary Completion Date

August 25, 2021

Completion Date

July 7, 2022

Last Updated

October 12, 2022

Enrollment

ACTUAL participants

Conditions

PsychosisSubstance UseSubstance Use DisordersFamilyTobacco UseNicotine Use DisorderCigarette SmokingCannabisMarijuanaAlcohol Use DisorderAlcoholSchizophreniaSchizoaffective DisorderBipolar DisorderMental Disorder

Interventions

CRAFT-FT

BEHAVIORAL

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

NCT04197921

Opioid-use DisorderSubstance Use Disorders

View study

RECRUITINGPHASE1/PHASE2

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

NCT07226895

Clinical High Risk for Psychosis (CHR)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 12, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Families With Substance Use and Psychosis: A Pilot Study

Inclusion Criteria

Exclusion Criteria

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

ACP-204 in Adults With Alzheimer's Disease Psychosis

Primary Connections for Youth and Families

Gii'Igoshimong: Sitting With Your First Family